ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,046.07
      0.82%
      US Tech 100
      21,029.62
      0.77%
      Dow Jones
      43,934.78
      1.03%
      Brent Oil
      78.525
      -0.88%
      Bitcoin
      107,000.00
      4.87%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Cardiol Therapeutics Inc (CRDL) Quote

      Cardiol Therapeutics Inc

      Cardiol Therapeutics Inc (CRDL)

      Cordel Group Plc
      Cardiol Therapeutics Inc
      1.225
      0.015
      ( 1.24% )
      Updated: 13:38:34
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      1.225
      Bid
      1.22
      Ask
      1.23
      Volume
      150,651
      1.21 Day's Range 1.24
      0.9595 52 Week Range 3.12
      Market Cap
      99.964M
      Previous Close
      1.21
      Open
      1.2303
      Last Trade
      500
      @
      1.225
      Last Trade Time
      13:38:34
      Financial Volume
      $ 184,210
      VWAP
      1.2228
      Average Volume (3m)
      375,825
      Shares Outstanding
      81,603,422
      Dividend Yield
      -
      PE Ratio
      -5.08
      Earnings Per Share (EPS)
      -0.34
      Revenue
      -
      Net Profit
      -28.13M

      About Cardiol Therapeutics Inc

      Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solut... Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Show more

      Sector
      Coml Physical, Biologcl Resh
      Industry
      Coml Physical, Biologcl Resh
      Headquarters
      Oakville, Ontario, Can
      Founded
      -
      Cardiol Therapeutics Inc is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker CRDL. The last closing price for Cardiol Therapeutics was $1.21. Over the last year, Cardiol Therapeutics shares have traded in a share price range of $ 0.9595 to $ 3.12.

      Cardiol Therapeutics currently has 81,603,422 shares outstanding. The market capitalization of Cardiol Therapeutics is $98.74 million. Cardiol Therapeutics has a price to earnings ratio (PE ratio) of -5.08.

      Ask ADVFN Intelligence (AI)

      CRDL Latest News

      More News

      FeaturedLuke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program

      3 hours ago

      PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

      Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics...

      December 19 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      November 18 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      November 14 2024
      Edgar (US Regulatory)

      Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

      NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL...

      November 13 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      October 22 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      October 11 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      October 10 2024
      Edgar (US Regulatory)

      Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

      October 09 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      October 09 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.045-3.543307086611.271.31.172567691.22414564CS
      4-0.055-4.2968751.281.511.172654261.29990811CS
      12-0.615-33.42391304351.842.241.173758251.55391345CS
      26-0.905-42.48826291082.132.631.173946361.81924177CS
      520.14513.42592592591.083.120.95954215511.90035375CS
      156-0.715-36.85567010311.943.120.452670481.51520611CS
      260-1.405-53.42205323192.634.960.453329082.02003772CS

      CRDL - Frequently Asked Questions (FAQ)

      What is the current Cardiol Therapeutics share price?
      The current share price of Cardiol Therapeutics is $ 1.225
      How many Cardiol Therapeutics shares are in issue?
      Cardiol Therapeutics has 81,603,422 shares in issue
      What is the market cap of Cardiol Therapeutics?
      The market capitalisation of Cardiol Therapeutics is USD 98.74M
      What is the 1 year trading range for Cardiol Therapeutics share price?
      Cardiol Therapeutics has traded in the range of $ 0.9595 to $ 3.12 during the past year
      What is the PE ratio of Cardiol Therapeutics?
      The price to earnings ratio of Cardiol Therapeutics is -5.08
      What is the reporting currency for Cardiol Therapeutics?
      Cardiol Therapeutics reports financial results in CAD
      What is the latest annual profit for Cardiol Therapeutics?
      The latest annual profit of Cardiol Therapeutics is CAD -28.13M
      What is the registered address of Cardiol Therapeutics?
      The registered address for Cardiol Therapeutics is 2265 UPPER MIDDLE ROAD EAST, SUITE 602, OAKVILLE, ONTARIO, L6H 0C3
      Which industry sector does Cardiol Therapeutics operate in?
      Cardiol Therapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      USEGUS Energy Corp
      $ 4.5201
      (94.83%)
      		90.84M
      ASSTAsset Entities Inc
      $ 0.8486
      (82.69%)
      		242.6M
      GCTKGlucoTrack Inc
      $ 0.1226
      (44.41%)
      		452.59M
      DOGZDogness International Corporation
      $ 25.84
      (42.76%)
      		1.32M
      RGTIRigetti Computing Inc
      $ 13.36
      (35.91%)
      		177.21M
      GOEVCanoo Inc
      $ 0.3522
      (-73.91%)
      		34.7M
      HEPAHepion Pharmaceuticals Inc
      $ 0.296
      (-36.89%)
      		621.73k
      ORKTOrangeKloud Technology Inc
      $ 0.7532
      (-32.75%)
      		6.19M
      WNWMeiwu Technology Company Ltd
      $ 0.2653
      (-27.81%)
      		8.53M
      FTAIFTAI Aviation Ltd
      $ 83.0882
      (-26.06%)
      		13.59M
      GCTKGlucoTrack Inc
      $ 0.1227
      (44.52%)
      		454.09M
      CRKNCrown Electrokinetics Corporation
      $ 0.1194
      (-4.48%)
      		355.81M
      ASSTAsset Entities Inc
      $ 0.8486
      (82.69%)
      		243.09M
      RGTIRigetti Computing Inc
      $ 13.365
      (35.96%)
      		177.37M
      RIMEAlgorhythm Holdings Inc
      $ 0.035
      (-15.87%)
      		145.98M

      CRDL Discussion

      View Posts
      Monksdream Monksdream 1 month ago
      CRDL, under $2
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL SHORT SQUEEZE ALERTS

      Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL

      Cardiol Therapeutics MAvERIC-Pilot Study Results:

      Safety: High tolerability and 95% compliance.

      Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
      👍️0
      MahinAgency MahinAgency 2 months ago
      A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL

      Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

      Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL

      Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

       MAvERIC-Pilot Results:
      Safety: High tolerance, 95% compliance.
      Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL MAvERIC-Pilot Study:

      Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

      👍️0
      MahinAgency MahinAgency 2 months ago
      Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
      👍️0
      MahinAgency MahinAgency 2 months ago
      INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
      👍️0
      MahinAgency MahinAgency 2 months ago
      $CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

      ❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

      ❤️Episodes of pericarditis per year substantially reduced 

      ❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
      and the Phase III MAVERIC-3 clinical trials

      Congratulations to all long term shareholders! 
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL BIG NEWS:

      Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
      👍️0
      MahinAgency MahinAgency 2 months ago
      Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

      Valued at $9 per share, assuming $609M in sales

      Valued at $1 per share, assuming $132M in sales
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL RED TO GREEN, Looks Good

      Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

      Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

       Valued at $9 per share, assuming $609M in sales by 2033

      Valued at $1 per share, assuming $132M in sales by 2033
      👍 1
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

      Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL lets See Red To Green, 

      H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

      The company recently raised $13.5 million
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
      👍️0
      MahinAgency MahinAgency 2 months ago
      Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

      The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
      👍️0
      tw0122 tw0122 2 months ago
      30 million shares offering at .26 October 30th
      👍️0
      MahinAgency MahinAgency 2 months ago
      H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

      MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
      👍️0
      MahinAgency MahinAgency 2 months ago
      $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL SHORT SQUEEZE ALERTS

      H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

      MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
      👍️0
      MahinAgency MahinAgency 2 months ago
      Key Points:

      Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
      New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
      Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
      Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

      Recently raised $13.5 million to fund developments?
      👍️0
      MahinAgency MahinAgency 2 months ago
      Big coming Next week 💃💃💃💃
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL
      ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

      Promising early results, potential approval by 2027, targeting $609M peak sales

      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

      $CRDL BIG SHORT SQUEEZE 
      👍️0
      tw0122 tw0122 2 months ago
      Chart looking good $2.07 next targets $4
      👍️0
      glenn1919 glenn1919 2 months ago
      CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

      Cardiol had around $21 million in cash at the end of Q1 


      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL
       Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

      The 12-month price target is $10
      👍️0
      MahinAgency MahinAgency 2 months ago
      NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
      👍️0
      MahinAgency MahinAgency 3 months ago
      Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
      👍️0
      MahinAgency MahinAgency 3 months ago
      $CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

      Cardiol sets a 12-month price target of $10
      👍️0
      MahinAgency MahinAgency 3 months ago
      NASDAQ: $CRDL Short Squeeze Allerts 

      A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
      👍️0
      MahinAgency MahinAgency 3 months ago
      Volume looks GOOD 💃💃🚀
      👍️0

      Your Recent History

      NASDAQ
      CRDL
      Cardiol Therapeutics
      TG
      A3515F
      Fresenius
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads